CYTENA

Cytena is a German biotechnology startup founded in 2014 that aims to revolutionize modern therapies. The company's mission is to streamline and advance biotherapeutic drug development by providing precise control of individual cells through automation and microtechnology. Cytena's instruments offer automated isolation of single cells with assurance of clonality, high viability rates, and purity. These features make their instruments compatible with cell line development, single cell analysis, and downstream applications. Notably, major pharmaceutical companies have successfully integrated Cytena's instruments into their workflows for efficient monoclonal cell line production. In March 2019, Cytena received a significant boost with a €3.00M Series A investment led by HTGF (High-Tech Gruenderfonds). This investment reflects the industry's confidence in Cytena's potential to make a substantial impact in the biotechnology and healthcare sectors. The company's commitment to innovation is further underscored by their proactive approach to hiring, as they are actively seeking motivated individuals to join their dynamic team and contribute to the development of cutting-edge products. Cytena's dedication to accelerate drug development, combined with their recent investment, positions them as a noteworthy player in the evolving landscape of healthcare technology.